Lin JK, Moran AE, Bibbins-Domingo K, et al. – Researchers developed microsimulation models to evaluate the cost-effectiveness of a polypill containing aspirin, lisinopril, atenolol, and simvastatin for secondary prevention of atherosclerotic cardiovascular disease—a principal cause of morbidity and mortality worldwide—in comparison with current care in China, India, Mexico, Nigeria, and South Africa. They used the Prospective Urban Rural Epidemiological study to model baseline use of secondary prevention drugs. In contrast with current care for secondary prevention of atherosclerotic cardiovascular disease in China, India, Mexico, Nigeria, and South Africa, the polypill was found to be cost-effective, especially when made accessible at public-sector pricing. However, achieving significant improvements in cardiovascular health will require concurrent investments in health infrastructure to improve the uptake of the polypill among individuals with established atherosclerotic cardiovascular disease.